Shalini Sharp joined our Board of Directors in September 2024.

Ms. Sharp is a leading financial executive with extensive experience in the pharmaceutical and investment banking industries. Ms. Sharp currently serves as a board member of Neurocrine Biosciences, Organon & Co and Septerna. Previously, she served on the boards of Mirati Therapeutics, Sutro Biopharma, Precision Biosciences, and Panacea Acquisition Corp.

Ms. Sharp previously served as Chief Financial Officer and Executive Vice President at Ultragenyx and Chief Financial Officer and Vice President at Agenus. She previously held positions at Elan Pharmaceuticals, McKinsey & Company and Goldman Sachs.

Ms. Sharp earned a B.A. and an MBA from Harvard University.